Quantcast

Latest Roche Group Stories

2014-08-07 16:27:47

-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy (SMA). Scientists from Roche Pharma Research and Early Development...

2014-07-29 12:35:02

Company's two-booth approach allows customers to see how Roche is partnering with them today and tomorrow CHICAGO, July 29, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at the American Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo today by unveiling two booths (#1209 and #2009) focused on the unique ways Roche is partnering with customers to redefine the value of the laboratory. "Our customers tell us every day that they're looking for a...

2014-06-10 16:26:58

LAVAL, QC, June 10, 2014 /CNW Telbec/ - Roche announced that Health Canada approved the cobas® 4800 HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche has also launched the fully automated CINtec® PLUS test to improve the detection and early intervention of pre-cancerous cervical disease. The Health Canada approved CINtec® PLUS cytology test helps identify women with high-grade pre-cancerous cervical...

2014-05-20 16:27:01

Formation of strategic alliance designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized predictive treatment INDIANAPOLIS, May 20, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. Established in 2002, Roche's MCOE program is...

2014-04-29 12:31:02

CHICAGO, April 29, 2014 /PRNewswire/ -- Roche Diagnostics has selected HY Connect, an independent, full-service agency, as a marketing and communications partner. Headquartered in Indianapolis, Indiana, Roche Diagnostics is the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche Diagnostics is also part of one of the world's leading research-oriented healthcare organizations - the Roche Group. HY Connect gained the...

2014-04-24 16:29:10

Expanded indication makes cobas® HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older PLEASANTON, Calif., April 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)announced today that the U.S. Food and Drug Administration (FDA) approved the cobas(®) HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12...

2014-03-27 12:30:04

TUCSON, Ariz., March 27, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group has made an educational grant to support the World Health Organization (WHO) Clinical Advisory Meeting being held March 31 through April 1, 2014 in Chicago. The meeting's purpose is to update the existing WHO monograph on Tumours of the Haematopoietic and Lymphoid Tissues published in 2008. The meeting will be attended by up to 100 global experts in the field of...

2014-03-12 20:24:30

PLEASANTON, Calif., March 12, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas® HPV (Human Papillomavirus) Test as a first-line primary screening tool in women 25 years and older to assess their risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA outweigh...

2014-03-11 08:31:51

TUCSON, March 11, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a multi-year agreement with Bayer Pharma AG (Bayer) to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer's portfolio of targeted therapy projects. This new agreement extends an already existing collaboration and focuses on the development of diagnostic tests for Bayer's biomarker targeted...

2014-03-05 12:27:23

TUCSON, Ariz., March 5, 2014 /PRNewswire/ -- An international panel of leaders in the pathology community today announced its support of four principles designed to drive positive change and improve patient safety in the anatomic pathology laboratory. The "Principles for Pathology and Patient Safety" address key issues where the expressed need for standardization and solutions is most acute. At the invitation of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, the panel...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related